Navidea Biopharmaceutica (Israel) Performance

NAVB -- Israel Stock  

ILS 49.30  2.00  4.23%

The company secures Beta (Market Risk) of -0.6136 which conveys that as returns on market increase, returns on owning Navidea Biopharmaceutica are expected to decrease at a much smaller rate. During bear market, Navidea Biopharmaceutica is likely to outperform the market. Although it is extremely important to respect Navidea Biopharmaceutica price patterns, it is better to be realistic regarding the information on equity historical price patterns. The philosophy towards estimating future performance of any stock is to evaluate the business as a whole together with its past performance including all available fundamental and technical indicators. By analyzing Navidea Biopharmaceutica technical indicators you can presently evaluate if the expected return of 0.0% will be sustainable into the future. Navidea Biopharmaceutica right now secures a risk of 0.0%. Please verify Navidea Biopharmaceuticals Treynor Ratio, Value At Risk, Downside Variance, as well as the relationship between Maximum Drawdown and Potential Upside to decide if Navidea Biopharmaceuticals will be following its current price movements.

Risk-Adjusted Performance

Over the last 30 days Navidea Biopharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Navidea Biopharmaceutica is not utilizing all of its potentials. The current stock price disturbance, may contribute to short term losses for the investors.
Fifty Two Week Low43.00
Fifty Two Week High50.50
Horizon     30 Days    Login   to change

Navidea Biopharmaceutica Relative Risk vs. Return Landscape

If you would invest  4,930  in Navidea Biopharmaceuticals on March 26, 2019 and sell it today you would earn a total of  0.00  from holding Navidea Biopharmaceuticals or generate 0.0% return on investment over 30 days. Navidea Biopharmaceuticals is generating negative expected returns and assumes 0.0% volatility on return distribution over the 30 days horizon. Simply put, 0% of equities are less volatile than Navidea Biopharmaceutica and 99% of equity instruments are likely to generate higher returns than the company over the next 30 trading days.
 Daily Expected Return (%) 
      Risk (%) 

Navidea Biopharmaceutica Market Risk Analysis

Sharpe Ratio = 0.0
Good Returns
Average Returns
Small Returns
Based on monthly moving average Navidea Biopharmaceutica is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Navidea Biopharmaceutica by adding it to a well-diversified portfolio.

Navidea Biopharmaceutica Alerts

Equity Alerts and Improvement Suggestions

Navidea Biopharmaceutica is not yet fully synchronised with the market data
Navidea Biopharmaceutica has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations
The company reported revenue of 1.45M. Net Loss for the year was (19.16M) with profit before overhead, payroll, taxes, and interest of 1.81M.
Please see also Stocks Correlation. Please also try Fundamentals Matrix module to view fundamentals matrix and analyze how accounts are interrelated and interconnected with each other.